Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities

References

• Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697–712.
   PubMed Web of Science ®Google Scholar
• Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther. 2009;31(Pt 2):2349–2370.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345–1377.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 July 01;36(7):1703–1719.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):984–997.
   PubMed Web of Science ®Google Scholar
• DiNardo CD. Ivosidenib in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2018 Sep 20;379(12):1186.
   PubMedGoogle Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Glasdegib: first Global Approval. Drugs. 2019 Feb;79(2):207–213.
   PubMed Web of Science ®Google Scholar
• Jen EY, Ko CW, Lee JE, et al. FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018 Jul 15;24(14):3242–3246.
   PubMed Web of Science ®Google Scholar
• Krauss AC, Gao X, Li L, et al. FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res. 2019 May 1;25(9):2685–2690.
   PubMed Web of Science ®Google Scholar
• Alharbi RA, Pettengell R, Pandha HS, et al. The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia. 2013 May 01;27(5):1000–1008.
   PubMed Web of Science ®Google Scholar
• Bhatlekar S, Fields JZ, Boman BM. Role of HOX genes in stem cell differentiation and cancer. Stem Cells Int. 2018;2018:3569493.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 January 01;30(1):41–47.
   PubMed Web of Science ®Google Scholar
• Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899–902.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Wang Z, Wysocka J, et al. Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression. Mol Cell Biol. 2004;24(13):5639–5649.
   PubMed Web of Science ®Google Scholar
• Borkin D, He S, Miao H, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015 Apr 13;27(4):589–602.
   PubMed Web of Science ®Google Scholar
• Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367(6477):586–590.
   PubMed Web of Science ®Google Scholar
• Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020 Feb 3;130(2):981–997.
   PubMed Web of Science ®Google Scholar
• Miao H, Kim E, Chen D, et al. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. Blood. 2020 Dec 17;136(25):2958–2963.
   PubMed Web of Science ®Google Scholar
• Libura M, Asnafi V, Tu A, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood. 2003 Sep 15;102(6):2198–2204.
   PubMed Web of Science ®Google Scholar
• Wang ES, Altman JK, Pettit K, et al. Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 2020 November 05;136:7–8.
   Google Scholar
• Davis JA, Fiskus WC, Daver N, et al. Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models. Blood. 2021;138(Supplement 1):3357–3357.
   Google Scholar
• Krivtsov AV, Evans K, Gadrey JY, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019;36(6):660–673.e11.
   PubMed Web of Science ®Google Scholar
• Fiskus WC, Mill CP, Birdwell C, et al. Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models. Blood. 2021;138(Supplement 1):3340–3340.
   Google Scholar
• Stein EM, Aldoss I, DiPersio JF, et al. Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: a Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101). Blood. 2021;138(Supplement 1):699–699.
   Google Scholar
• Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011 Jul 12;20(1):66–78.
   PubMed Web of Science ®Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12;20(1):53–65.
   PubMed Web of Science ®Google Scholar
• Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018 Jun 14;131(24):2661–2669.
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug 3;478(7370):524–528.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Gudgin EJ, Horton SJ, et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014 Feb;28(2):311–320.
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Lu C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013 Sep 15;27(18):1974–1985.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu Q, Acharya P, et al. High-resolution mapping of RNA polymerases identifies mechanisms of sensitivity and resistance to BET inhibitors in t(8;21) AML. Cell Rep. 2016 Aug 16;16(7):2003–2016.
   PubMed Web of Science ®Google Scholar
• Berthon C, Raffoux E, Thomas X, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016 Apr;3(4):e186–95.
   PubMed Web of Science ®Google Scholar
• Stoddard BL, Koshland DE Jr. Structure of isocitrate dehydrogenase with alpha-ketoglutarate at 2.7-A resolution: conformational changes induced by decarboxylation of isocitrate. Biochemistry. 1993 Sep 14;32(36):9317–9322.
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015 Feb;21(2):178–184.
   PubMed Web of Science ®Google Scholar
• Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015 Jun 25;372(26):2481–2498.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019 Nov;33(11):2575–2584.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 Nov;22(11):1597–1608.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Stein EM, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2021 Jan 1;39(1):57–65.
   PubMed Web of Science ®Google Scholar
• Caravella JA, Lin J, Diebold RB, et al. Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 Inhibitor. J Med Chem. 2020 Feb 27;63(4):1612–1623.
   PubMed Web of Science ®Google Scholar
• Watts JM, Baer MR, Yang J, et al. Olutasidenib (FT-2102), an IDH1m inhibitor as a single agent or in combination with azacitidine, Induces deep clinical responses with mutation clearance in patients with acute myeloid leukemia treated in a phase 1 dose escalation and expansion study. Blood. 2019;134(Supplement_1):231–231.
   Google Scholar
• Konteatis Z, Artin E, Nicolay B, et al. Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett. 2020;11(2):101–107.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Penas-Prado M, Peters KB, et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase i trial. Clin Cancer Res. 2021 Aug 15;27(16):4491–4499.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Z, Li Y, et al. Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China. Acta Pharm Sin B. 2021 Jun;11(6):1526–1540.
   PubMed Web of Science ®Google Scholar
• Brooks N, DeWalt R, Boulet S, et al. Abstract LB-274: identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1). 2019.
   Google Scholar
• Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol. 2012 Jan;180(1):2–11.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016 Oct;107(10):1422–1429.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Dombret H, Merchant A, et al. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019 Nov;15(31):3531–3545.
   PubMed Web of Science ®Google Scholar
• Short NJ, Borthakur G, Pemmaraju N, et al. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 Sep;63(9):2161–2170.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Schuster M, Joris M, et al. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Ann Hematol. 2022 Aug;101(8):1689–1701.
   PubMed Web of Science ®Google Scholar
• Bixby D, Noppeney R, Lin TL, et al. Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. Br J Haematol. 2019 May;185(3):595–598.
   PubMed Web of Science ®Google Scholar
• Tibes R, Kosiorek HE, Dueck A, et al. Phase I/IB study of azacitidine and hedgehog pathway inhibition with sonidegib (LDE225) in myeloid malignancies. Blood. 2017 December 08;130:2629.
   Web of Science ®Google Scholar
• Larson RA, Mandrekar SJ, Huebner LJ, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 Sep;35(9):2539–2551.
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the European society for blood and marrow transplantation. Haematologica. 2020 Jun;105(6):1507–1516.
   PubMed Web of Science ®Google Scholar
• Burchert A, Bug G, Finke J, et al. Sorafenib As maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial. Blood. 2018;132(Supplement 1):661–661.
   Google Scholar
• Levis MJ, Hamadani M, Logan B, et al. A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. J clin oncol. 2018;36(15_suppl):7075.
   Web of Science ®Google Scholar
• Swaminathan M, Kantarjian HM, Levis M, et al. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 Aug 1;106(8):2121–2130.
   PubMed Web of Science ®Google Scholar
• Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022 Oct 27;140(17):1845–1857.
   PubMed Web of Science ®Google Scholar
• Maiti A, DiNardo CD, Daver NG, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 Feb 1;11(2):25.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ryu H, Choi HK, et al. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive acute myeloid leukemia. Anticancer Res. 2021 Feb;41(2):731–737.
   PubMed Web of Science ®Google Scholar
• Yu Z, Du J, Hui H, et al. LT–171–861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. Theranostics. 2021;11(1):93–106.
   PubMed Web of Science ®Google Scholar
• Chen S, Benbarche S, Abdel-Wahab O. Splicing factor mutations in hematologic malignancies. Blood. 2021 Aug 26;138(8):599–612.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011 Dec 8;118(24):6239–6246.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 Sep 11;478(7367):64–69.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013 Mar;88(3):201–206.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Tang JL, Lin CT, et al. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 2013 Nov;88(11):E277–82.
   PubMed Web of Science ®Google Scholar
• Alsafadi S, Houy A, Battistella A, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016 Feb 4;7:10615.
   PubMed Web of Science ®Google Scholar
• El Marabti E, Abdel-Wahab O. Therapeutic modulation of RNA splicing in malignant and non-malignant disease. Trends Mol Med. 2021 Jul;27(7):643–659.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Wermke M, Klimek VM, et al. Results of a clinical trial of H3B-8800, a splicing modulator, in patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood. 2019;134(Supplement_1):673–673.
   Google Scholar
• Fong JY, Pignata L, Goy PA, et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 2019 Aug 12;36(2):194–209.e9.
   PubMed Web of Science ®Google Scholar
• Patel MR, Monga V, Jauhari S, et al. A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies. Blood. 2021;138(Supplement 1):2609–2609.
   Google Scholar
• Han T, Goralski M, Gaskill N, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017 Apr 28;356:6336.
   Web of Science ®Google Scholar
• Assi R, Kantarjian HM, Kadia TM, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 Jul 1;124(13):2758–2765.
   PubMed Web of Science ®Google Scholar
• Smith MA, Choudhary GS, Pellagatti A, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019 May;21(5):640–650.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Leslie LA, Younes A, et al. Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 inhibitor, for treatment of patients with relapsed or refractory hematologic malignancies: results from the phase 1 study. Blood. 2020;136(Supplement 1):44–45.
   Google Scholar
• Zitouni S, Nabais C, Jana SC, et al. Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol. 2014 July 01;15(7):433–452.
   PubMed Web of Science ®Google Scholar
• Renner AG, Dos Santos C, Recher C, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 2009 Jul 16;114(3):659–662.
   PubMed Web of Science ®Google Scholar
• Rudolph D, Steegmaier M, Hoffmann M, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009 May 1;15(9):3094–3102.
   PubMed Web of Science ®Google Scholar
• Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014 Aug 28;124(9):1426–1433.
   PubMed Web of Science ®Google Scholar
• Cortes J, Podoltsev N, Kantarjian H, et al. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan;113(1):92–99.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Ridinger M, Lin TL, et al. A phase ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2020 Dec 1;26(23):6132–6140.
   PubMed Web of Science ®Google Scholar
• Navada SC, Garcia-Manero G, OdchimarReissig R, et al. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: results of a phase 1 study. Leuk Res. 2020;94:106369.
   PubMed Web of Science ®Google Scholar
• Lambert JM, Moshfegh A, Hainaut P, et al. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010 Mar 4;29(9):1329–1338.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Descamps G, Moreau P, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood. 2014 Sep 4;124(10):1626–1636.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Komrokji RS, DeZern AE, et al. Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood. 2021;138(Supplement 1):246–246.
   PubMedGoogle Scholar
• Cluzeau T, Sebert M, Rahme R, et al. Eprenetapopt Plus Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase ii study by the groupe francophone des myelodysplasies (GFM). J Clin Oncol. 2021 May 10;39(14):1575–1583.
   PubMed Web of Science ®Google Scholar
• Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996 Oct 1;15(19):5349–5357.
   PubMed Web of Science ®Google Scholar
• Lehmann C, Friess T, Birzele F, et al. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. J Hematol Oncol. 2016 Jun 28;9(1):50.
   PubMedGoogle Scholar
• Yee K, Papayannidis C, Vey N, et al. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1/1b study small star, filled. Leuk Res. 2021;100:106489.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Beckermann BM, Catalani O, et al. MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncol. 2020 May;16(13):807–815.
   PubMed Web of Science ®Google Scholar
• Daver NG, Garcia JS, Jonas BA, et al. Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood. 2019;134(Supplement_1):229–229.
   Google Scholar
• Erba HP, Becker PS, Shami PJ, et al. Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). J clin oncol. 2017;35(15_suppl):7027–7027.
   Google Scholar
• Sallman DA, McLemore AF, Aldrich AL, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136(24):2812–2823.
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012 Apr;24(2):225–232.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Malki MA, Asch AS, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results. J clin oncol. 2020;38(15_suppl):7507–7507.
   Web of Science ®Google Scholar
• Zeidan AM, DeAngelo DJ, Palmer J, et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022 Mar;101(3):557–569.
   PubMed Web of Science ®Google Scholar
• Williams P, Basu S, Garcia‐Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 May 1;125(9):1470–1481.
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun;28(6):1280–1288.
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019 Mar;9(3):370–383.
   PubMed Web of Science ®Google Scholar
• Gojo I, Stuart RK, Webster J, et al. Multi-Center Phase 2 Study of Pembrolizumab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients. Blood. 2019;134(Supplement_1):832–832.
   Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97–111.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Komrokji RS, Brunner AM. TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther. 2021 May 04;21(5):523–534.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Esteve J, Porkka K, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): final Analysis from a Phase Ib Study. Blood. 2021;138(Supplement 1):244–244.
   Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015 Mar;93(3):290–296.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013 Apr;3(4):388–398.
   PubMed Web of Science ®Google Scholar
• O’Hear C, Heiber JF, Schubert I, et al. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica. 2015 Mar;100(3):336–344.
   PubMed Web of Science ®Google Scholar
• Liu F, Zhang H, Sun L, et al. First-in-human Cll1-Cd33 Compound Car (Ccar) T cell therapy in relapsed and refractory acute myeloid Leukemia: Eha Library; 2020 [2022-November-11]. Available from: https://library.ehaweb.org/eha/2020/eha25th/294969/fang.liu.first-in-human.cll1-cd33.compound.car.28ccar29.t.cell.therapy.in.html
   Google Scholar
• Budde L, Song JY, Kim Y, et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Blood. 2017 December 08;130:811.
   Web of Science ®Google Scholar
• Cui Q, Qian C, Xu N, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021 May 25;14(1):82.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Elmariah H, Sweet K, et al. Phase 1/1b safety study of prgn-3006 ultracar-t in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes. Blood. 2021;138(Supplement 1):825–825.
   Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Wang R, Wang X, et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020 May 26;4(10):2192–2201.
   PubMed Web of Science ®Google Scholar
• Bazinet A, Assouline S. A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3.’ Expert Rev Hematol. 2021 Feb;14(2):185–197.
   PubMed Web of Science ®Google Scholar
• Russell-Smith TA, Gurskyte L, Muresan B, et al. Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review. Future Oncol. 2022 May;18(16):2029–2039.
   PubMed Web of Science ®Google Scholar
• Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022 Jul 12;6(13):3997–4005.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239–3246.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Luo L, Hsu V, et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res. 2019 Jun 1;25(11):3205–3209.
   PubMed Web of Science ®Google Scholar
• Cerchione C, Romano A, Daver N, et al. IDH1/IDH2 inhibition in acute myeloid leukemia. Front Oncol. 2021;11:639387.
   PubMedGoogle Scholar
• McMurry H, Fletcher L, Traer E. IDH inhibitors in AML-promise and pitfalls. Curr Hematol Malig Rep. 2021 Apr;16(2):207–217.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Kadia TM, DiNardo CD, et al. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021 Apr 15;127(8):1186–1207.
   PubMed Web of Science ®Google Scholar
• Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019 Jun;32(2):145–153.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, By K, Subramaniam S, et al. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019 Oct 15;25(20):6021–6025.
   PubMed Web of Science ®Google Scholar
• Mustafa Ali MK, Corley EM, Alharthy H, et al. Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a propensity score-adjusted cohort study. Front Oncol. 2022;12:858202.
   PubMed Web of Science ®Google Scholar
• Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamicin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. results of the GOELAMS AML 2006 IR study. Blood. 2011;118(21):79–79.
   Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011 Feb 1;29(4):369–377.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012 Apr 21;379(9825):1508–1516.
   PubMed Web of Science ®Google Scholar
• Kovtun Y, Jones GE, Adams S, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018 Apr 24;2(8):848–858.
   PubMed Web of Science ®Google Scholar
• Thol F, Schlenk RF, Heuser M, et al. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015 Jul 16;126(3):319–327.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013 May 16;121(20):4056–4062.
   PubMed Web of Science ®Google Scholar
• Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011 Jul 1;29(19):2709–2716.
   PubMed Web of Science ®Google Scholar
• Haznedaroglu IC, Beyazit Y. Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis. Clin Sci (Lond). 2013 Mar;124(5):307–323.
   PubMed Web of Science ®Google Scholar
• Turk S, Turk C, Akbar MW, et al. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide. PLoS One. 2020;15(11):e0242497.
   PubMed Web of Science ®Google Scholar
• Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552–1564.
   PubMed Web of Science ®Google Scholar